You are required to be logged in to access the full website
Click here if you have forgotten your username or password
Therapy Areas
18 October 2019 - - US-based biopharmaceutical company Incyte (NASDAQ: INCY) has received positive 52-week results from its randomised, double-blind, dose-ranging, Phase 2 study evaluating ruxolitinib cream, a nonsteroidal, anti-inflammatory, JAK inh...
18 October 2019 - - US-based biopharmaceutical company Harbour BioMed has completed a Phase 2 study in China of HBM9036 (tanfanercept), a new, investigational TNF receptor-1 fragment, in adult patients with moderate-to-severe Dry-Eye-Disease, the com...
18 October 2019 - - US-based protein engineering company Forbius's Phase 1a solid tumor trial exploring the safety and tolerability of AVID200, a first-in-class TGF-beta 1 and 3 selective inhibitor, administered as a monotherapy has fully enroll...
18 October 2019 - - US-based biotechnology company Eyevensys has presented results from part 1 of its phase I/II study for non-infectious uveitis at the Ophthalmology Innovation Summit's 11th Annual OIS@AAO conference on October 10, 2019 in San ...
18 October 2019 - - US-based biopharmaceutical company Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) has presented results from its recently completed Phase 2 dose-ranging trial of the investigational medicine CTP-543 in patients with moderate-to...
18 October 2019 - - The National Institute for Health and Care Excellence has recommended that women with relapsed ovarian cancer in England have access to rucaparib through the Cancer Drugs Fund, US-based Clovis Oncology, Inc. (NASDAQ: CLVS) said.
18 October 2019 - - US-based health intelligence company Sema4 has launched Expanded Carrier Screen with Personalized Residual Risk, a carrier screening option, to provide physicians and their patients with enhanced risk assessment analysis designed ...